LYEL Lyell Immunopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LYEL

Price (delayed)

$10.53

Market cap

$258.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.83

Enterprise value

$220.4M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 33

Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies, including three product candidates in or entering Phase 1 clinical development for patients with solid tumors ...

Highlights
The EPS rose by 47% year-on-year and by 7% since the previous quarter
The net income rose by 25% year-on-year
The gross profit has plunged by 53% YoY and by 14% from the previous quarter
The revenue has dropped by 53% year-on-year and by 14% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.lyell.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of LYEL

LYEL stock price

How has the Lyell Immunopharma stock price performed over time
Intraday
-5.56%
1 week
-2.27%
1 month
-32.2%
1 year
-20.11%
YTD
-65.79%
QTD
-25.05%

Financial performance

How have Lyell Immunopharma's revenue and profit performed over time
Revenue
$25,000
Gross profit
$25,000
Operating income
-$256.5M
Net income
-$248.48M
Gross margin
100%
Net margin
-993,908%
Lyell Immunopharma's net margin has shrunk by 59% YoY and by 17% QoQ
The gross profit has plunged by 53% YoY and by 14% from the previous quarter
The revenue has dropped by 53% year-on-year and by 14% since the previous quarter
The operating margin has dropped by 53% year-on-year and by 16% since the previous quarter

Price vs fundamentals

How does LYEL's price correlate with its fundamentals

Growth

What is Lyell Immunopharma's growth rate over time

Valuation

What is Lyell Immunopharma stock price valuation
P/E
N/A
P/B
1.05
P/S
9,840.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,816.05
The EPS rose by 47% year-on-year and by 7% since the previous quarter
The stock's P/B is 31% less than its last 4 quarters average of 1.6 and 15% less than its 5-year quarterly average of 1.3
Lyell Immunopharma's equity has decreased by 22% YoY and by 15% from the previous quarter
LYEL's price to sales (P/S) is 143% more than its 5-year quarterly average of 4294.5 but 19% less than its last 4 quarters average of 12900.7
The revenue has dropped by 53% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Lyell Immunopharma business performance
The return on sales has dropped by 59% year-on-year and by 17% since the previous quarter
Lyell Immunopharma's ROIC has decreased by 8% YoY and by 7% from the previous quarter
The ROE has contracted by 7% YoY and by 7% from the previous quarter
The ROA is down by 6% since the previous quarter and by 2.3% year-on-year

Dividends

What is LYEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LYEL.

Financial health

How did Lyell Immunopharma financials performed over time
LYEL's quick ratio is down by 32% year-on-year and by 25% since the previous quarter
The current ratio has declined by 30% year-on-year and by 26% since the previous quarter
Lyell Immunopharma's debt is 84% lower than its equity
Lyell Immunopharma's equity has decreased by 22% YoY and by 15% from the previous quarter
Lyell Immunopharma's debt has decreased by 21% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.